Leuprolide (Lupron*, Lupron Depot*)

Category:

  • Hormonal

Description:

  • Luteinizing hormone-releasing hormone (LH-RH) agonist, inhibits gonadotropin secretion

Indications:

  • Advanced prostatic cancer

  • Central precocious puberty

  • Endometriosis

  • Uterine fibroids

Contraindications:

  • Pregnancy and lactation

  • Undiagnosed vaginal bleeding

  • 30mg depot formulation is contraindicated in women

Precautions:

  • Pregnancy category X

  • Increase in occurrence of disease (prostatic and endometriosis) during initial phases of treatment.

  • May cause bone density changes

Adverse Reactions (Side Effects):

  • ECG changes and ischemia (19.4%)

  • Injection site irritation (13.8%)

  • Edema (12.2%)

  • Hot flashes and sweating (47-84%)

  • Generalized pain (6-32%)

  • Decrease in testicular size  

Dosage:

  • Administered by injection

  • Advanced prostatic cancer: 1mg SQ daily or 7.5mg IM monthly or 22.5mg IM every three months or 30mg IM every four months

  • Central precocious puberty: individualize dose per patient based on weight

  • < 25kg = 7.5mg IM every four weeks

  • 25-37.5kg = 11.25mg IM every four weeks

  • >37.5kg = 15mg IM every four weeks

  • Endometriosis: 3.75mg IM monthly or 11.25mg IM every three months

  • Uterine fibroids: recommended therapy less than 3 months

  • 3.75mg IM monthly or 11.25mg IM once for three months

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300  

*Lupron and Lupron Depot are the registered trademarks of TAP Pharmaceutical Products Inc., 675 North Field Drive, Lake Forest, Illinois 60045. For further information, go to  www.tap.com

Gynecology and Obstetrics CD-ROM
Volumes 1-6
2004 Edition
 Lippincott Williams & Wilkins
Copyright 2004
All Rights Reserved